News
Early Access and Financial Benefits: Like the Gateway Program for our Specialty Master’s degrees, you can take up to nine ...
The analysis of FDA-approved next-in-class drugs also found that, among RCTs with head-to-head trials, fewer than 1 in 4 of ...
Stocktwits on MSN10h
Replimune Stock Catches Retail Fire As Analyst Says FDA Shakeup Removes 'Major Obstacle' For Skin Cancer Drug's Potential Approval
Retail trader buzz around Replimune Group surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ...
Jacob Sands, MD, discusses the data that support the FDA accelerated approval of Dato-DXd in EGFR-positive non–small cell ...
Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), has stepped down, with market analysts forecasting a boost to the cell and ...
As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, ...
The iBox Scoring System is a novel composite biomarker endpoint predictive of long-term graft survival after kidney ...
On July 22, 2025, the US Food and Drug Administration (FDA) started accepting applications to participate in the Commissioner’s National ...
Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne's first planned ...
Shipments of Elevidys for nonambulatory DMD patients remain suspended while the Company evaluates an enhanced immunosuppressive regimen for these patients.
The Revell family hoped a gene therapy could buy time for their sons, who have a rare and fatal disease. After two patients ...
The FDA recently unveiled a new national priority voucher program that would seek to trade faster drug approvals for lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback